Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 7
2014 24
2015 29
2016 106
2017 166
2018 206
2019 268
2020 415
2021 552
2022 559
2023 479
2024 575
2025 648
2026 324

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,806 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Neuen BL, Fletcher RA, Heath L, Perkovic A, Vaduganathan M, Badve SV, Tuttle KR, Pratley R, Gerstein HC, Perkovic V, Heerspink HJL. Neuen BL, et al. Circulation. 2024 Nov 26;150(22):1781-1790. doi: 10.1161/CIRCULATIONAHA.124.071689. Epub 2024 Aug 30. Circulation. 2024. PMID: 39210781
We estimated treatment effects by baseline SGLT2 inhibitor use using inverse variance-weighted meta-analysis. The main cardiovascular outcomes were major adverse cardiovascular events (nonfatal myocardial infarction, stroke, or cardiovascular …
We estimated treatment effects by baseline SGLT2 inhibitor use using inverse variance-weighted meta-analysis. The main card …
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.
Preda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S, Liberale L. Preda A, et al. Cardiovasc Res. 2024 Apr 30;120(5):443-460. doi: 10.1093/cvr/cvae047. Cardiovasc Res. 2024. PMID: 38456601 Free PMC article. Review.
An increasing number of individuals are at high risk of type 2 diabetes (T2D) and its cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD), and eventually premature death. The sodium-glucose co-transporter-2 (SGLT2) protein sits i …
An increasing number of individuals are at high risk of type 2 diabetes (T2D) and its cardiovascular complications, including heart f …
Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis.
Yan Q, Chen X, Yu C, Yin Y. Yan Q, et al. BMC Cardiovasc Disord. 2024 Nov 22;24(1):663. doi: 10.1186/s12872-024-04316-w. BMC Cardiovasc Disord. 2024. PMID: 39578752 Free PMC article.
The sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin (EMPA) has been demonstrated to reduce the risk of cardiovascular mortality or hospitalization for heart failure (HF) in patients. Nevertheless, data concerning the long-term cardiovascular …
The sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin (EMPA) has been demonstrated to reduce the risk of cardi …
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.
Cowie MR, Fisher M. Cowie MR, et al. Nat Rev Cardiol. 2020 Dec;17(12):761-772. doi: 10.1038/s41569-020-0406-8. Epub 2020 Jul 14. Nat Rev Cardiol. 2020. PMID: 32665641 Review.
In large cardiovascular outcome trials in patients with diabetes, SGLT2 inhibitors improve cardiovascular and renal outcomes, including hospitalization for heart failure, with this benefit extending to patients without diabetes who have heart fa …
In large cardiovascular outcome trials in patients with diabetes, SGLT2 inhibitors improve cardiovascular and re …
Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. van der Aart-van der Beek AB, et al. Nat Rev Nephrol. 2022 May;18(5):294-306. doi: 10.1038/s41581-022-00535-6. Epub 2022 Feb 10. Nat Rev Nephrol. 2022. PMID: 35145275 Review.
After observations that sodium-glucose co-transporter 2 (SGLT2) inhibitors - originally developed as glucose-lowering agents - improved cardiovascular and renal outcomes in patients with type 2 diabetes, dedicated trials were initiated to evaluate the card …
After observations that sodium-glucose co-transporter 2 (SGLT2) inhibitors - originally developed as glucose-lowering agents - improv …
Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure.
Modzelewski KL, Pipilas A, Bosch NA. Modzelewski KL, et al. JAMA Netw Open. 2024 May 1;7(5):e249305. doi: 10.1001/jamanetworkopen.2024.9305. JAMA Netw Open. 2024. PMID: 38696170 Free PMC article.
The comparative outcomes of SGLT2 inhibitors relative to each other has not been well defined and may impact medication selection. ...Eligible patients had a diagnosis of heart failure, had never received an SGLT2 inhibitor previously, and were newly s …
The comparative outcomes of SGLT2 inhibitors relative to each other has not been well defined and may impact medication select …
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease.
Alicic RZ, Neumiller JJ, Tuttle KR. Alicic RZ, et al. Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i3-i17. doi: 10.1093/ndt/gfae212. Nephrol Dial Transplant. 2025. PMID: 39907543 Free PMC article. Review.
These health conditions therefore comprise what is now known as cardiovascular-kidney-metabolic (CKM) syndrome. Recently approved medications, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the n …
These health conditions therefore comprise what is now known as cardiovascular-kidney-metabolic (CKM) syndrome. Recently approved med …
Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.
Palmer BF, Clegg DJ. Palmer BF, et al. Clin J Am Soc Nephrol. 2021 Aug;16(8):1284-1291. doi: 10.2215/CJN.17621120. Epub 2021 Feb 9. Clin J Am Soc Nephrol. 2021. PMID: 33563658 Free PMC article. Review.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower plasma glucose concentration by inhibiting Na(+)-glucose-coupled transport in the proximal tubule. Clinical trials demonstrate these drugs have favorable effects on cardiovascular outco …
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower plasma glucose concentration by inhibiting Na(+)-glucos …
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Siddiqui R, Obi Y, Dossabhoy NR, Shafi T. Siddiqui R, et al. Curr Hypertens Rep. 2024 Dec;26(12):463-474. doi: 10.1007/s11906-024-01314-3. Epub 2024 Jun 24. Curr Hypertens Rep. 2024. PMID: 38913113 Free PMC article. Review.
Unfortunately, efficacy data in dialysis patients is lacking as ESKD was an exclusion criterion for all major clinical trials of SGLT2 inhibitors. This review explores the potential of SGLT2 inhibitors in improving cardiovascular outcomes among patient …
Unfortunately, efficacy data in dialysis patients is lacking as ESKD was an exclusion criterion for all major clinical trials of SGLT2 …
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.
Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang EH, Ky B, Lenihan D, Nohria A, Dani SS, Ganatra S. Avula V, et al. JACC Heart Fail. 2024 Jan;12(1):67-78. doi: 10.1016/j.jchf.2023.08.026. Epub 2023 Oct 25. JACC Heart Fail. 2024. PMID: 37897456 Free article.
Patients receiving guideline-directed medical therapy were divided into 2 groups based on SGLT2 inhibitor use. After propensity score matching, odds ratios (ORs) and Cox proportional HRs were used to compare outcomes over a 2-year follow-up period. ...All-cau …
Patients receiving guideline-directed medical therapy were divided into 2 groups based on SGLT2 inhibitor use. After propensit …
3,806 results